Cookies used for improved website experience

Siemens Healthineers and our partners use cookies and other similar technologies to operate the Siemens Healthineers websites and personalize content and ads. You may find out more about how we use cookies by clicking "Show details" or by referring to our Cookie Policy.
You may allow all cookies or select them individually. And you may change your consent and cookie preferences anytime by clicking on the "Review and change your consent" button on the Cookie Policy page.

ELF Test as a universally available prognostic tool for enhanding NASH patient care

The ELF Test as a Universally Available Prognostic Tool for Enhancing NASH Patient Care

Perspectives from hepatology and endocrinology

The Enhanced Liver Fibrosis (ELF™) Test​ is the first blood test granted De Novo marketing authorization by FDA for prognosis in advanced fibrosis due to NASH​. Watch this program to hear the clinical perspectives from two clinical thought leaders on how they see the ELF Test positively impacting care for NASH patients with advanced liver fibrosis.

Moderator

Roma Levy

H. Roma Levy, MS

Clinical Expert, Liver Disease
Siemens Healthineers

Speakers

Scott Isaacs

Dr. Scott D. Isaacs

Endocrinologist and Obesity Medicine Specialist
Atlanta Endocrine Associates, Atlanta, GA

Mazen Noureddin

Dr. Mazen Noureddin

Director of Fatty Liver Program
Cedars Sinai, Los Angeles, CA